Showing results (421-430 of 909) with videos related to

Sort By:
Pageof 91
Kidney International Reports|February 3, 2026
A FIDELITY Analysis on Finerenone With SGLT-2i and GLP-1RA in CKDAjay K Singh, Stefan D Anker, Bertram Pitt, et al.
The American Journal of Medicine|August 5, 2018
Role of High-Dose Beta-Blockers in Patients with Heart Failure with Preserved Ejection Fraction and Elevated Heart RatePhillip H Lam, Neha Gupta, Daniel J Dooley, et al.
The New England Journal of Medicine|March 11, 2011
Irbesartan in patients with atrial fibrillation, Salim Yusuf, Jeff S Healey, et al.
Circulation|December 1, 2004
Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) studyMariya P Tokmakova, Hicham Skali, Satish Kenchaiah, et al.
Journal of the American College of Cardiology|May 12, 2012
Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) programDavide Castagno, Hicham Skali, Madoka Takeuchi, et al.
European Journal of Heart Failure|September 29, 2005
Pulsatile hemodynamic effects of candesartan in patients with chronic heart failure: the CHARM ProgramGary F Mitchell, J Malcolm O Arnold, Mark E Dunlap, et al.
European Journal of Heart Failure|March 1, 2014
Prognosis and response to therapy of first inpatient and outpatient heart failure event in a heart failure clinical trial: MADIT-CRTHicham Skali, Edward M Dwyer, Robert Goldstein, et al.
The American Journal of Cardiology|March 25, 2008
Comparison of renal function and cardiovascular risk following acute myocardial infarction in patients with and without diabetes mellitusNagesh S Anavekar, Scott D Solomon, John J V McMurray, et al.
European Journal of Heart Failure|October 1, 2022
Sacubitril/valsartan and loop diuretic requirement in heart failure with preserved ejection fraction in the PARAGON-HF trialSafia Chatur, Brian L Claggett, Orly Vardeny, et al.
Clinical Trials (London, England)|February 16, 2012
Midcourse correction to a clinical trial when the event rate is underestimated: the Look AHEAD (Action for Health in Diabetes) StudyFrederick L Brancati, Mary Evans, Curt D Furberg, et al.
Pageof 91